Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model

In vitro Time Kill of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli using Cation Adjusted Muller Hinton Broth and ISO-Sensitest Broth

(2022) Maxwell J. Lasko et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints

(2022) Andrew J. Fratoni et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity and In Vivo Efficacy of Cefiderocol Against Stenotrophomonas maltophilia

(2021) Rio Nakamura et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Advances in the Microbiology of Stenotrophomonas maltophilia

(2021) Joanna S. Brooke   CLINICAL MICROBIOLOGY REVIEWS

Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision

(2021) Andrew J Fratoni et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

(2021) Pranita D Tamma et al.   CLINICAL INFECTIOUS DISEASES

The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study

(2020) Bin Cai et al.   Open Forum Infectious Diseases

Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug resistant Stenotrophomonas maltophilia

(2020) M Biagi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans

(2019) Jürgen B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim

(2018) Jee Hyun Park et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

(2018) Veronica Rico Caballero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment and modelling of antibacterial combination regimens

(2018) G.G. Rao et al.   CLINICAL MICROBIOLOGY AND INFECTION

Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy

(2017) Anthony A. Adegoke et al.   Frontiers in Microbiology

Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis

(2016) N. Alsaad et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis

(2009) A. C. Cheng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issue

(2008) K. T. Wisell et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY